S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com - Stifel has resumed coverage of Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and set a price target of $89.00, according to a research note released Monday. The stock, currently trading near its 52-week high of $61.00, has shown remarkable momentum with a 45% gain year-to-date. InvestingPro data reveals that 5 analysts have recently revised their earnings estimates upward for the upcoming period.
The research firm highlighted Mirum’s "cash-flow positive, high-growth commercial business" and its mid- to late-stage pipeline with multiple growth opportunities, including a pivotal catalyst expected in the second quarter of 2026 for primary sclerosing cholangitis (PSC). This assessment aligns with the company’s impressive 62.3% revenue growth over the last twelve months, according to InvestingPro data.
Stifel expressed optimism about growth prospects for Livmarli, citing multiple "upside-levers" including organic growth in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), weight-based pricing, and the EXPAND program, alongside steady revenue from Ctexli and Cholbam.
The firm also conveyed "strong conviction" in volixibat ahead of pivotal PSC/primary biliary cholangitis (PBC) data, projecting it as a potential blockbuster opportunity even with conservative assumptions.
Stifel noted that Mirum’s strong financial position, growing commercial business, pipeline optionality, and management team make it stand out "in what remains a discerning biotech tape," despite the stock’s recent strong performance.
In other recent news, Mirum Pharmaceuticals reported strong second-quarter 2025 financial results, with total revenues reaching $127.8 million. This marks a significant 64% increase compared to the same period in 2024, surpassing expectations of $107.36 million. The company also reported an earnings per share of -$0.12, which was better than the anticipated -$0.33. Following these results, Mirum Pharmaceuticals raised its 2025 revenue guidance to a range of $490 million to $510 million, indicating a projected 48% year-over-year growth at the midpoint. In light of these developments, H.C. Wainwright increased its price target for the company to $80, maintaining a Buy rating. Similarly, JMP Securities raised its price target to $81, with a Market Outperform rating, citing strong sales of Livmarli and bile acids. These updates reflect the company’s positive financial trajectory and analyst confidence in its future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.